Literature DB >> 27800529

Epidemiology of Norovirus Infection Among Immunocompromised Patients at a Tertiary Care Research Hospital, 2010-2013.

Karin Bok1, D Rebecca Prevots2, Alison M Binder2, Gabriel I Parra1, Sara Strollo2, Gary A Fahle3, Allison Behrle-Yardley1, Jordan A Johnson1, Eric A Levenson1, Stanislav V Sosnovtsev1, Steven M Holland2, Tara N Palmore4, Kim Y Green1.   

Abstract

Background.  Noroviruses are a major cause of infectious gastroenteritis worldwide, and viruses can establish persistent infection in immunocompromised individuals. Risk factors and transmission in this population are not fully understood. Methods.  From 2010 through 2013, we conducted a retrospective review among immunocompromised patients (n = 268) enrolled in research studies at the National Institutes of Health Clinical Center and identified a subset of norovirus-positive patients (n = 18) who provided stool specimens for norovirus genotyping analysis. Results.  Norovirus genome was identified by reverse-transcription quantitative polymerase chain reaction in stools of 35 (13%) of the 268 immunocompromised patients tested, and infection prevalence was 21% (11 of 53) in persons with primary immune deficiencies and 12% (20 of 166) among persons with solid tumors or hematologic malignancies. Among 18 patients with norovirus genotyping information, norovirus GII.4 was the most prevalent genotype (14 of 18, 78%). Persistent norovirus infection (≥6 months) was documented in 8 of 18 (44%) individuals. Phylogenetic analysis of the GII.4 capsid protein sequences identified at least 5 now-displaced GII.4 variant lineages, with no evidence of their nosocomial transmission in the Clinical Center. Conclusions.  Norovirus was a leading enteric pathogen identified in this immunocompromised population. Both acute and chronic norovirus infections were observed, and these were likely community-acquired. Continued investigation will further define the role of noroviruses in these patients and inform efforts toward prevention and treatment.

Entities:  

Keywords:  epidemiology; immunocompromised; norovirus

Year:  2016        PMID: 27800529      PMCID: PMC5084716          DOI: 10.1093/ofid/ofw169

Source DB:  PubMed          Journal:  Open Forum Infect Dis        ISSN: 2328-8957            Impact factor:   3.835


  46 in total

1.  GII.4 Sydney_2012 norovirus infection in immunocompromised patients in Beijing and its rapid evolution in vivo.

Authors:  Huan Mai; Yan Gao; Xu Cong; Hui Wang; Ning Liu; Xiaojun Huang; Lanping Xu; Yuhong Chen; Lai Wei
Journal:  J Med Virol       Date:  2015-08-26       Impact factor: 2.327

Review 2.  Norovirus infection in immunocompromised hosts.

Authors:  K Y Green
Journal:  Clin Microbiol Infect       Date:  2014-08       Impact factor: 8.067

3.  Recombination within the pandemic norovirus GII.4 lineage.

Authors:  John-Sebastian Eden; Mark M Tanaka; Maciej F Boni; William D Rawlinson; Peter A White
Journal:  J Virol       Date:  2013-03-27       Impact factor: 5.103

4.  Proposal for a unified norovirus nomenclature and genotyping.

Authors:  Annelies Kroneman; Everardo Vega; Harry Vennema; Jan Vinjé; Peter A White; Grant Hansman; Kim Green; Vito Martella; Kazuhiko Katayama; Marion Koopmans
Journal:  Arch Virol       Date:  2013-04-25       Impact factor: 2.574

5.  Diversity of enteric viruses detected in patients with gastroenteritis in a tertiary referral paediatric hospital.

Authors:  Chris I Gallimore; David W Cubitt; Alison F Richards; Jim J Gray
Journal:  J Med Virol       Date:  2004-07       Impact factor: 2.327

6.  Evolutionary dynamics of GII.4 noroviruses over a 34-year period.

Authors:  Karin Bok; Eugenio J Abente; Mauricio Realpe-Quintero; Tanaji Mitra; Stanislav V Sosnovtsev; Albert Z Kapikian; Kim Y Green
Journal:  J Virol       Date:  2009-09-16       Impact factor: 5.103

7.  Noroviruses: The Most Common Pediatric Viral Enteric Pathogen at a Large University Hospital After Introduction of Rotavirus Vaccination.

Authors:  Hoonmo L Koo; Frederick H Neill; Mary K Estes; Flor M Munoz; Arlin Cameron; Herbert L DuPont; Robert L Atmar
Journal:  J Pediatric Infect Dis Soc       Date:  2012-08-03       Impact factor: 3.164

8.  Immunogenetic mechanisms driving norovirus GII.4 antigenic variation.

Authors:  Lisa C Lindesmith; Martina Beltramello; Eric F Donaldson; Davide Corti; Jesica Swanstrom; Kari Debbink; Antonio Lanzavecchia; Ralph S Baric
Journal:  PLoS Pathog       Date:  2012-05-17       Impact factor: 6.823

9.  Sequence analysis of the capsid gene during a genotype II.4 dominated norovirus season in one university hospital: identification of possible transmission routes.

Authors:  Barbara Juliane Holzknecht; Kristina Træholt Franck; Rikke Thoft Nielsen; Blenda Böttiger; Thea Kølsen Fischer; Jannik Fonager
Journal:  PLoS One       Date:  2015-01-15       Impact factor: 3.240

Review 10.  A systematic review and meta-analysis of the global seasonality of norovirus.

Authors:  Sharia M Ahmed; Benjamin A Lopman; Karen Levy
Journal:  PLoS One       Date:  2013-10-02       Impact factor: 3.240

View more
  7 in total

Review 1.  Emergence of norovirus strains: A tale of two genes.

Authors:  Gabriel I Parra
Journal:  Virus Evol       Date:  2019-11-25

2.  Generation of Norovirus-Specific T Cells From Human Donors With Extensive Cross-Reactivity to Variant Sequences: Implications for Immunotherapy.

Authors:  Ryo Hanajiri; Gelina M Sani; Devin Saunders; Patrick J Hanley; Abha Chopra; Simon A Mallal; Stanislav V Sosnovtsev; Jeffrey I Cohen; Kim Y Green; Catherine M Bollard; Michael D Keller
Journal:  J Infect Dis       Date:  2020-02-03       Impact factor: 5.226

Review 3.  Diagnosis and management of gastrointestinal complications in adult cancer patients: 2017 updated evidence-based guidelines of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Medical Oncology (DGHO).

Authors:  M Schmidt-Hieber; J Bierwirth; D Buchheidt; O A Cornely; M Hentrich; G Maschmeyer; E Schalk; J J Vehreschild; Maria J G T Vehreschild
Journal:  Ann Hematol       Date:  2017-11-24       Impact factor: 3.673

4.  Human Norovirus Evolution in a Chronically Infected Host.

Authors:  Sylvie Y Doerflinger; Stefan Weichert; Anna Koromyslova; Martin Chan; Christian Schwerk; Ruediger Adam; Stefan Jennewein; Grant S Hansman; Horst Schroten
Journal:  mSphere       Date:  2017-03-29       Impact factor: 4.389

5.  Healthcare-Associated SARS-CoV-2 Reinfection after 3 Months with a Phylogenetically Distinct Omicron Variant: A Case Report.

Authors:  Kim Callebaut; Anke Stoefs; Dimitri Stylemans; Oriane Soetens; Florence Crombé; Ellen Vancutsem; Hideo Imamura; Ingrid Wybo; Deborah De Geyter; Denis Piérard; Astrid Muyldermans; Thomas Demuyser
Journal:  Viruses       Date:  2022-08-23       Impact factor: 5.818

6.  Intra-Host Evolution of Norovirus GII.4 in a Chronic Infected Patient With Hematopoietic Stem Cell Transplantation.

Authors:  Jie-Mei Yu; Ze-Yin Liang; Ke Guo; Xiao-Man Sun; Qing Zhang; Yu-Jun Dong; Zhao-Jun Duan
Journal:  Front Microbiol       Date:  2020-03-09       Impact factor: 5.640

7.  Infectious Norovirus Is Chronically Shed by Immunocompromised Pediatric Hosts.

Authors:  Amy Davis; Valerie Cortez; Marco Grodzki; Ronald Dallas; Jose Ferrolino; Pamela Freiden; Gabriela Maron; Hana Hakim; Randall T Hayden; Li Tang; Adam Huys; Abimbola O Kolawole; Christiane E Wobus; Melissa K Jones; Stephanie M Karst; Stacey Schultz-Cherry
Journal:  Viruses       Date:  2020-06-05       Impact factor: 5.048

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.